Sanofi to acquire Protein Sciences
(Thomson Reuters ONE) -
Sanofi to acquire Protein Sciences
- Acquisition adds recombinant-based influenza vaccine
to Sanofi Pasteur's portfolio -
Paris, France - July 11, 2017 - Sanofi announced today it will acquire Protein
Sciences, a privately held vaccines biotechnology company based in Meriden,
Connecticut in the United States. Under the terms of the agreement, Sanofi will
make an upfront payment of $650 million and pay up to $100 million upon
achievement of certain milestones.
Protein Sciences received approval from the US Food and Drug Administration
(FDA) in October 2016 for their Flublok(®) Quadrivalent Influenza Vaccine (QIV).
Flublok(®) is the only recombinant protein-based influenza vaccine approved by
the FDA.
"The acquisition of Protein Sciences will allow us to broaden our flu portfolio
with the addition of a non-egg based vaccine," said David Loew, Sanofi Executive
Vice President and Head of Sanofi Pasteur, Sanofi's vaccines division.
"Protein Sciences was actively looking for an opportunity to grow its business,
particularly in the US," said Manon M.J. Cox, President and Chief Executive
Officer, Protein Sciences. "As part of Sanofi Pasteur, we expect our Flublok(®)
influenza vaccine to benefit from Sanofi Pasteur's expertise in the field of
influenza vaccines."
The acquisition, which has been unanimously approved by the board of directors
of Protein Sciences and a majority of Protein Sciences shareholders, is expected
to close in the third quarter of 2017, subject to customary regulatory
approvals.
About Protein Sciences
Protein Sciences is a privately held biotech company established in 1983 and
headquartered in Meriden, CT. Protein Sciences' mission is to save lives and
improve health through the creation of innovative vaccines and
biopharmaceuticals.
About Sanofi Pasteur
Sanofi Pasteur produces vaccines against seasonal influenza on its four sites:
Swiftwater (Pennsylvania, United States), Val de Reuil (France), Ocoyoacac
(Mexico City, Mexico) and Shenzhen (China).
About Sanofi
Sanofi, a global healthcare leader, discovers, develops and distributes
therapeutic solutions focused on patients' needs. Sanofi is organized into five
global business units: Diabetes and Cardiovascular, General Medicines and
Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Consumer Healthcare. Sanofi
is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
Sanofi Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private
Securities Litigation Reform Act of 1995, as amended. Forward-looking statements
are statements that are not historical facts. These statements include
projections and estimates and their underlying assumptions, statements regarding
plans, objectives, intentions and expectations with respect to future financial
results, events, operations, services, product development and potential, and
statements regarding future performance. Forward-looking statements are
generally identified by the words "expects", "anticipates", "believes",
"intends", "estimates", "plans" and similar expressions. Although Sanofi's
management believes that the expectations reflected in such forward-looking
statements are reasonable, investors are cautioned that forward-looking
information and statements are subject to various risks and uncertainties, many
of which are difficult to predict and generally beyond the control of Sanofi,
that could cause actual results and developments to differ materially from those
expressed in, or implied or projected by, the forward-looking information and
statements. These risks and uncertainties include among other things, the
uncertainties inherent in research and development, future clinical data and
analysis, including post marketing, decisions by regulatory authorities, such as
the FDA or the EMA, regarding whether and when to approve any drug, device or
biological application that may be filed for any such product candidates as well
as their decisions regarding labelling and other matters that could affect the
availability or commercial potential of such product candidates, the absence of
guarantee that the product candidates if approved will be commercially
successful, the future approval and commercial success of therapeutic
alternatives, Sanofi's ability to benefit from external growth opportunities
and/or obtain regulatory clearances, risks associated with intellectual property
and any related pending or future litigation and the ultimate outcome of such
litigation, trends in exchange rates and prevailing interest rates, volatile
economic conditions, the impact of cost containment initiatives and subsequent
changes thereto, the average number of shares outstanding as well as those
discussed or identified in the public filings with the SEC and the AMF made by
Sanofi, including those listed under "Risk Factors" and "Cautionary Statement
Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for
the year ended December 31, 2016. Other than as required by applicable law,
Sanofi does not undertake any obligation to update or revise any forward-looking
information or statements.
Contacts:
Media Relations Investor Relations
Jack Cox George Grofik
Tel. : +33 (0)1 53 77 46 46 Tel.: +33 (0)1 53 77 45 45
mr(at)sanofi.com ir(at)sanofi.com
Press Release (PDF):
http://hugin.info/152918/R/2119470/807205.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Sanofi via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 11.07.2017 - 07:00 Uhr
Sprache: Deutsch
News-ID 551724
Anzahl Zeichen: 6784
contact information:
Town:
PARIS
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 227 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Sanofi to acquire Protein Sciences"
steht unter der journalistisch-redaktionellen Verantwortung von
Sanofi (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
